Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma Ratnasingam, S, Casan, J, Shortt, J, Hawkes, E, Gilbertson, M, McQuilten, Z, Grigoriadis, G, Htun, KT, Htet, SM, Campbell, Philip, Chai, KL, Quach, H, Patil, S and Opat, S 2019, Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma, Scientific Reports, vol. 9, pp. 1-7, doi: 10.1038/s41598-019-49776-9. Attached Files Name Description MIMEType Size Downloads Title Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma Author(s) Ratnasingam, S Casan, J Shortt, J Hawkes, E Gilbertson, M McQuilten, Z Grigoriadis, G Htun, KT Htet, SM Campbell, Philip Chai, KL Quach, H Patil, S Opat, S Journal name Scientific Reports Volume number 9 Article ID 13544 Start page 1 End page 7 Total pages 7 Publisher Nature Place of publication London, Eng. Publication date 2019 ISSN 2045-2322 Summary The role of cytarabine-based induction and autologous stem cell transplantation (ASCT) in front-line treatment of younger patients with mantle cell lymphoma (MCL) is well established, however the utility of intensive approaches in older patients remains unclear. This retrospective study compared first line treatment outcomes in patients aged 60 years or more, treated at six tertiary centres between 2000–2015. 70 patients included had a median age of 69 (60–91) and most (94%) demonstrated advanced stage disease. Treatment regimens included: R-CHOP-like (n = 39), alternating R-CHOP/R-DHAC (n = 10), R-HyperCVAD/R-MA (n = 7), R-CHOP/Cytarabine (Nordic Protocol) (n = 10) and other (n = 4). 16 patients underwent an ASCT. The median follow-up for surviving patients was 37 months. Compared to R-CHOP-like therapies, cytarabine-based regimens were associated with an improved overall response rate (ORR) of 70% vs 33% (p < 0.001) and overall survival (OS) (HR 0.541, [0.292–1.001], p = 0.05). No difference in efficacy between different cytarabine-based regimens was detected, but R-HyperCVAD/R-MA was associated with increased hospitalisation and transfusion requirements. Patients undergoing ASCT demonstrated an improved median OS (HR 0.108 [0.015–0.796], p = 0.029) but were significantly younger. These results reaffirm the use of cytarabine in MCL for selected patients aged over 60. Such regimens should be strongly considered for this population in frontline therapy. Language eng DOI 10.1038/s41598-019-49776-9 HERDC Research category C1 Refereed article in a scholarly journal Free to Read? Yes Persistent URL http://hdl.handle.net/10536/DRO/DU:30159556 Document type: Journal Article Collections: Faculty of Health School of Medicine Open Access Collection Related Links Link Description Link to full-text (open access)   Connect to Elements publication management system Go to link with your DU access privileges     Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au. Versions Version Filter Type Mon, 29 Nov 2021, 09:09:59 EST Mon, 29 Nov 2021, 15:04:36 EST Wed, 15 Dec 2021, 05:05:26 EST Thu, 17 Feb 2022, 09:31:58 EST Thu, 17 Feb 2022, 14:39:24 EST Thu, 17 Feb 2022, 14:45:09 EST Thu, 17 Feb 2022, 14:57:20 EST Filtered Full Citation counts:   Cited 0 times in TR Web of Science Cited 3 times in Scopus Search Google Scholar Access Statistics: 9 Abstract Views, 0 File Downloads  -  Detailed Statistics Created: Mon, 29 Nov 2021, 09:09:59 EST